1. [Valproic acid pharmacogenetics in an individual approach to treatment of women of childbearing age with epilepsy].
- Author
-
Snaĭder NA, Sychev DA, Piliugina MS, Dmitrenko DV, Bochanova EN, and Shapovalova EA
- Subjects
- Anticonvulsants administration & dosage, Anticonvulsants therapeutic use, Cytochrome P-450 CYP2C9, Female, Fertility, Folic Acid administration & dosage, Folic Acid metabolism, Humans, Mutation, Polymorphism, Genetic, Valproic Acid administration & dosage, Valproic Acid therapeutic use, Young Adult, Anticonvulsants adverse effects, Aryl Hydrocarbon Hydroxylases genetics, Epilepsy drug therapy, Folic Acid Deficiency chemically induced, Folic Acid Deficiency genetics, Methylenetetrahydrofolate Reductase (NADPH2) genetics, Precision Medicine, Valproic Acid adverse effects
- Abstract
A clinical case of the development of undesirable pharmacological phenomena in a woman of childbearing age with epilepsy is described. The development of undesirable pharmacological phenomena at reception of average therapeutic doses of valproic acid has been caused by the primary (idiopathic) and secondary (valproate-induced) infringement of a folic cycle against a combination of CYP2C9*3 gene polymorphism and a mutation in the MTHFR gene.
- Published
- 2011